{"gene":"PLK2","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":2003,"finding":"PLK2/Snk is a direct transcriptional target of p53; its kinase activity is negatively regulated by its C-terminus, and siRNA-mediated silencing in the presence of paclitaxel or nocodazole significantly increased apoptosis occurring in mitotic cells, indicating a p53-dependent mitotic checkpoint role.","method":"siRNA knockdown, mutagenesis, cell death assays in mitotic cells","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown with defined mitotic phenotype and mutagenesis, single lab but multiple orthogonal approaches","pmids":["12897130"],"is_preprint":false},{"year":2003,"finding":"Endogenous Snk/PLK2 kinase activity is detected in G1 phase; substitution of Thr-236 with glutamate increases kinase activity ~10-fold while Lys-108 substitution abolishes activity; GFP-C-Snk localizes to the microtubule organizing center in a polo-box-dependent manner; calcium- and integrin-binding protein CIB co-immunoprecipitates with Snk and inhibits its kinase activity, functioning as a negative regulator.","method":"Site-directed mutagenesis, kinase assays, GFP localization, Co-immunoprecipitation, in vitro kinase inhibition assay","journal":"Molecular cancer research : MCR","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro kinase assay with mutagenesis, Co-IP, and live-cell localization in a single study with multiple orthogonal methods","pmids":["12651910"],"is_preprint":false},{"year":1999,"finding":"Snk/PLK2 protein is targeted to dendrites of activated neurons following stimuli that produce synaptic plasticity (including LTP); a conserved C-terminal domain of Snk interacts specifically with CIB (Ca2+- and integrin-binding protein).","method":"Immunolocalization in neurons, yeast two-hybrid and binding assays for CIB interaction","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — direct localization experiment in neurons with functional context, interaction confirmed by binding assay, single lab","pmids":["10523297"],"is_preprint":false},{"year":2003,"finding":"Plk2-deficient mouse embryonic fibroblasts grow more slowly and show delayed entry into S phase; Plk2-null embryos show retarded growth and decreased cell proliferation in the labyrinthine zone of the placenta, establishing a role for Plk2 in cell cycle progression.","method":"Gene-targeted knockout mice, BrdU incorporation, cell growth assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with defined cellular phenotype (delayed S-phase entry) confirmed in both primary cells and in vivo","pmids":["12972611"],"is_preprint":false},{"year":2008,"finding":"PLK2 directly phosphorylates alpha-synuclein at Ser-129 in vitro; PLK kinase inhibitors reduced pSer-129 alpha-synuclein in primary cortical cultures and mouse brain in vivo; specific shRNA knockdown or knockout of Plk2 reduced pSer-129 levels, establishing PLK2 as a principal kinase for this modification in the CNS.","method":"In vitro biochemical phosphorylation assay, pharmacological inhibition, shRNA knockdown, PLK2 knockout mice","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution of phosphorylation, confirmed by genetic KO and pharmacological inhibition across multiple systems","pmids":["19004816"],"is_preprint":false},{"year":2010,"finding":"PLK2 directly phosphorylates CPAP (centrosomal P4.1-associated protein, human SAS-4 homologue) at S589 and S595 in vitro and in vivo; this phosphorylation is critical for procentriole formation during the centrosome cycle; phospho-resistant CPAP mutant fails to form elongated centrioles.","method":"In vitro kinase assay, phospho-site mutagenesis, cell cycle stage-specific phosphorylation analysis, overexpression of phospho-resistant mutant","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with mutagenesis and functional validation (procentriole formation defect), single lab but multiple orthogonal methods","pmids":["20531387"],"is_preprint":false},{"year":2008,"finding":"The polo-box domain of PLK2 is required for its centrosomal localization; mutation of critical polo-box residues prevents centrosomal localization and impairs centriole duplication; PLK2 localizes exclusively to the mother centriole in early G1 then distributes to both centrioles at S phase onset; PLK2-mediated centriole duplication depends on PLK4 function.","method":"Polo-box mutagenesis, immunofluorescence localization, siRNA knockdown, spindle analysis","journal":"Cell cycle (Georgetown, Tex.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization with functional consequence (centriole duplication), mutagenesis, single lab","pmids":["19001868"],"is_preprint":false},{"year":2010,"finding":"PLK2 directly interacts with NSF (N-ethylmaleimide-sensitive fusion protein) and disrupts the NSF-GluA2 interaction, promoting loss of surface GluA2 AMPAR subunit, greater association of GluA2 with PICK1 and GRIP1, and decreased synaptic AMPAR current; this effect requires PLK2-NSF engagement but not PLK2 kinase activity, and occurs through a motif in PLK2 independent of canonical polo-box sites.","method":"Co-immunoprecipitation, surface receptor assays, electrophysiology in rat hippocampal neurons, domain-mapping mutagenesis","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — reciprocal Co-IP, electrophysiology, and domain mutagenesis in a single study with multiple orthogonal methods","pmids":["20802490"],"is_preprint":false},{"year":2011,"finding":"Plk2 directs phosphorylation-dependent ubiquitin-proteasome degradation of RasGRF1 (Ras activator) and SPAR (Rap inhibitor), and phosphorylation-dependent stimulation of SynGAP (Ras inhibitor) and PDZGEF1 (Rap activator); collectively these actions suppress Ras and activate Rap signaling; perturbation of Plk2 prevents homeostatic shrinkage and loss of dendritic spines and impairs memory formation.","method":"Genetic epistasis, phosphorylation assays, ubiquitin-proteasome pathway assays, dendritic spine imaging, behavioral memory tasks","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple substrates identified and validated, genetic perturbation with defined cellular and behavioral phenotypes, replicated across Ras/Rap regulators","pmids":["21382555"],"is_preprint":false},{"year":2012,"finding":"Plk2 directly phosphorylates Fbxw7 (human Cdc4/SCF ubiquitin ligase F-box protein) at serine 176; this phosphorylation destabilizes Fbxw7, leading to cyclin E accumulation and increased centriole duplication potential; the two proteins form a complex in vitro and in vivo.","method":"In vitro kinase assay, Co-immunoprecipitation, phospho-site mutagenesis, centriole counting assays","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with identified phosphosite, Co-IP in vitro and in vivo, functional centriole duplication assay, single lab with multiple orthogonal methods","pmids":["22399798"],"is_preprint":false},{"year":2009,"finding":"PLK2 interacts with endogenous TSC1 protein; a C-terminal PLK2-GST fusion protein binds both TSC1 and TSC2; cells overexpressing PLK2 show decreased phosphorylation of p70S6K (downstream mTOR target) during hypoxia, indicating PLK2 modulates mTOR signaling via TSC1/2 interaction.","method":"Co-immunoprecipitation, GST pulldown, p70S6K phosphorylation assay, tumor xenografts","journal":"Cell cycle (Georgetown, Tex.)","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — GST pulldown and Co-IP with functional mTOR readout, single lab","pmids":["20054236"],"is_preprint":false},{"year":2011,"finding":"PLK2 binds to and phosphorylates mutant p53, potentiating its oncogenic transcriptional activity; phosphorylated mutant p53 binds more efficiently to p300; Plk2 gene is transcriptionally regulated by both wild-type and mutant p53, forming an autoregulatory feedback loop.","method":"Co-immunoprecipitation, kinase assay, transcriptional reporter assays, siRNA knockdown","journal":"Cell cycle (Georgetown, Tex.)","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — Co-IP and kinase assay demonstrating direct interaction and phosphorylation, transcriptional assays, single lab","pmids":["22134238"],"is_preprint":false},{"year":2012,"finding":"PLK2 phosphorylates synGAP, shifting the ratio of synGAP GAP activity toward greater inactivation of HRas (65% increase) relative to Rap1 (16% increase); simultaneous phosphorylation by Plk2 and CDK5 at distinct sites produces additive increase in HRas GAP activity (~230%) and also increases GAP activity toward Rap2.","method":"In vitro kinase assay with recombinant synGAP, GTPase activity measurements, mass spectrometry identification of phosphosites","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution of kinase reaction with quantified substrate GAP activity, phosphosite identification by MS, single lab","pmids":["30049443"],"is_preprint":false},{"year":2013,"finding":"PLK2 genetic knockout in mouse brain produces a gene-dosage-dependent reduction of endogenous Ser129-phosphorylated alpha-synuclein in all brain regions examined; pharmacological inhibition with pan-PLK inhibitor BI 2536 did not further reduce residual pSer-129 in PLK2 KO mice, indicating PLK2 is the primary but not sole kinase for this modification in vivo.","method":"PLK2 knockout mice, heterozygous mice, pharmacological inhibition with BI 2536, brain regional pSer-129 alpha-synuclein quantification","journal":"Neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with dosage response, pharmacological epistasis, replicated across brain regions","pmids":["24128992"],"is_preprint":false},{"year":2012,"finding":"Alpha-synuclein is a substrate of yeast Cdc5 (PLK2 ortholog) and human PLK2; elevated levels of alpha-synuclein prevent Cdc5/Plk2 from maintaining normal GTP-bound Rho1 levels, disrupting MAPK stress signaling; the nine N-terminal amino acids of alpha-synuclein are essential for the interaction with polo-like kinases.","method":"Yeast genetics and biochemistry, GTP-Rho1 pull-down assay, N-terminal deletion mutagenesis of alpha-synuclein","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical interaction mapping with domain mutagenesis and GTPase assay, yeast and human cell experiments, single lab","pmids":["22988096"],"is_preprint":false},{"year":2012,"finding":"PLK2 is superior to CK2 as a catalyst of alpha-synuclein Ser-129 phosphorylation; acidic residues at positions n-3 (Glu-126) and n+2 (Glu-131) flanking Ser-129 are critical determinants for phosphorylation by PLK2, as their replacement with alanine abrogates phosphorylation.","method":"In vitro kinase assay with full-length alpha-synuclein and substituted peptides, comparison with CK2","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase reconstitution with systematic peptide substitution mutagenesis defining substrate specificity determinants, single lab","pmids":["22248692"],"is_preprint":false},{"year":2017,"finding":"PLK2 phosphorylates alpha-synuclein and promotes its selective degradation via macroautophagy; PLK2 and alpha-synuclein undergo co-degradation; the N-terminal region of alpha-synuclein is important for PLK2-mediated phosphorylation and physical interaction; PLK2 polyubiquitination is important for the PLK2-alpha-syn complex degradation by the macroautophagy machinery.","method":"Pharmacological and genetic inhibition of macroautophagy, domain mutagenesis, ubiquitination assays, Co-immunoprecipitation","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — multiple complementary approaches (genetic/pharmacological autophagy inhibition, Co-IP, domain mapping), single lab","pmids":["28154193"],"is_preprint":false},{"year":2015,"finding":"PLK2 directly phosphorylates TAp73 at Ser48 within the TA domain; phosphorylation is abolished by Ser48→Ala mutation; PLK2 physically binds TAp73; PLK2 inhibition combined with cisplatin leads to increased p21 and PUMA expression, cell cycle G1 arrest, increased apoptosis, and decreased invasion in TAp73-enriched osteosarcoma cells, effects absent in TAp73 knockdown cells.","method":"In vitro kinase assay, Co-immunoprecipitation, site-directed mutagenesis, siRNA knockdown, cell biology assays","journal":"Cancer medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — kinase assay with mutagenesis and functional validation, Co-IP, single lab","pmids":["26625870"],"is_preprint":false},{"year":2007,"finding":"PLK2 interacts with Chk2, Chk1, Ser317-phosphorylated Chk1, and p53 (by Co-immunoprecipitation); Plk2-deficient cells show higher H2AX Ser139 phosphorylation (indicating more DNA damage) and reduced Ser317-phosphorylated Chk1 under replication stress, indicating PLK2 contributes to S-phase checkpoint activation.","method":"Co-immunoprecipitation, siRNA knockdown, phospho-specific western blotting, cell death assays with aphidicolin/etoposide","journal":"Cell cycle (Georgetown, Tex.)","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — Co-IP demonstrating physical interactions, siRNA knockdown with checkpoint readout, single lab","pmids":["17912033"],"is_preprint":false},{"year":2018,"finding":"SIRT1 deacetylates Plk2; acetylation of Plk2 protects it from ubiquitination, while SIRT1-mediated deacetylation promotes ubiquitin-dependent Plk2 degradation; AURKA phosphorylates SIRT1 and promotes the SIRT1-Plk2 interaction during mitosis; in early-mid G1 phosphorylated SIRT1 deacetylates and degrades Plk2, while in late G1 hypophosphorylated SIRT1 has reduced Plk2 affinity allowing Plk2 accumulation at centrosomes for centriole duplication.","method":"Co-immunoprecipitation, acetylation/ubiquitination assays, deacetylase assay, cell cycle synchronization, centrosome imaging","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal biochemical assays defining PTM writer/eraser/reader relationship and functional centrosome consequence, single lab","pmids":["30517871"],"is_preprint":false},{"year":2015,"finding":"PLK2 indirectly activates ROCK2 via phosphorylating nucleophosmin (NPM); PLK4 functions downstream of ROCK2 to drive centrosome amplification; epistasis rescue assay placed PLK2 upstream of ROCK2 upstream of PLK4 in a linear centrosome amplification pathway.","method":"Centrosome amplification rescue assay, siRNA knockdown epistasis, kinase activity assays","journal":"Cell cycle (Georgetown, Tex.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with rescue assay placing PLK2 in linear pathway, single lab","pmids":["25590559"],"is_preprint":false},{"year":2014,"finding":"Plk2 regulates mitotic spindle orientation in mammary gland epithelium; loss of Plk2 leads to increased mammary epithelial cell proliferation, ductal hyperbranching, and loss of proper cell polarity, defining a role for Plk2 in spindle orientation and mammary gland development in vivo.","method":"Plk2 knockout mice, spindle orientation imaging, mammary gland morphology analysis, proliferation assays","journal":"Development (Cambridge, England)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mouse with defined cellular phenotype (spindle misorientation, polarity loss), single lab","pmids":["24598160"],"is_preprint":false},{"year":2023,"finding":"DYRK1A interacts with and phosphorylates PLK2 at Ser358; this phosphorylation increases PLK2 protein stability and markedly induces PLK2 kinase activity (evidenced by upregulation of alpha-synuclein S129 phosphorylation); DYRK1A-mediated PLK2 phosphorylation contributes to GBM cell proliferation, migration, and invasion.","method":"Co-immunoprecipitation, in vitro kinase assay, phospho-site mutagenesis, cell biology assays","journal":"International journal of oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and kinase assay with mutagenesis and functional validation, single lab","pmids":["37387444"],"is_preprint":false},{"year":2024,"finding":"PLK2 phosphorylates SQSTM1/p62 at S349 following proteasome inhibition; this phosphorylation strengthens SQSTM1 binding to KEAP1, required for formation of large SQSTM1 aggregates/bodies; PLK2 is upregulated upon proteasome inhibition and associates with SQSTM1.","method":"Co-immunoprecipitation, in vitro kinase assay, phospho-site mutagenesis, aggregate formation assays, proteasome inhibition experiments","journal":"Autophagy","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro kinase assay with identified phosphosite, Co-IP, and functional aggregate formation assay with mutagenesis validation, single lab","pmids":["39316746"],"is_preprint":false},{"year":2025,"finding":"PLK2 phosphorylates DCTN1 (dynactin 1) at S1098, impairing autophagosome-lysosome fusion and blocking autophagic flux; PLK2 overexpression promotes SNCA/alpha-synuclein PFF-induced aggregation (including of phosphorylation-resistant SNCAS129A) and neurotoxicity independently of S129 phosphorylation; genetic or pharmacological PLK2 inhibition reduced SNCA deposition and motor dysfunction in vivo.","method":"In vitro kinase assay, phospho-site identification, autophagy flux assays (LC3, LAMP1), autophagosome-lysosome fusion imaging, in vivo mouse model with genetic PLK2 suppression","journal":"Autophagy","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro kinase assay with substrate identification, multiple autophagy assays, in vivo validation, single lab with multiple orthogonal methods","pmids":["39773002"],"is_preprint":false},{"year":2023,"finding":"Plk2 directly phosphorylates N-cadherin and promotes its proteolytic processing and degradation during neuronal hyperexcitation; Plk2 also disrupts N-cadherin complexes with APP; loss of N-cadherin adhesive function destabilizes excitatory synapses as part of homeostatic synaptic plasticity.","method":"In vitro kinase assay, Co-immunoprecipitation, proteolytic processing assays, synaptic imaging in neurons","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — direct kinase assay and Co-IP with functional synaptic readout, single lab","pmids":["37654026"],"is_preprint":false},{"year":2021,"finding":"SKP1 directly interacts with PLK2 (by co-immunoprecipitation) and promotes PLK2 ubiquitination and protein degradation (by in vitro ubiquitination assay); reduced PLK2 due to SKP1-mediated degradation contributes to alpha-synuclein aggregation in neurons.","method":"Co-immunoprecipitation, in vitro ubiquitination assay, luciferase reporter for miRNA target validation","journal":"Journal of healthcare engineering","confidence":"Medium","confidence_rationale":"Tier 2-3 / Weak — Co-IP and in vitro ubiquitination assay from a single lab, modest methodological depth","pmids":["34234930"],"is_preprint":false},{"year":2026,"finding":"FAM117B interacts with DYRK1A and acts as its upstream regulator; DYRK1A induces PLK2 phosphorylation in colorectal cancer cells, thereby upregulating PLK2 protein expression; the FAM117B/DYRK1A/PLK2 axis promotes CRC cell proliferation, migration, and invasion.","method":"Co-immunoprecipitation, immunoprecipitation-kinase assay, knockdown/overexpression rescue experiments, in vivo xenograft model","journal":"Cell biology international","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — Co-IP and phosphorylation assay with functional epistasis rescue, single lab","pmids":["41504297"],"is_preprint":false},{"year":2024,"finding":"PLK2 phosphorylates GSK3β, increasing its phosphorylation (inactivation); PLK2 overexpression reduces oxidative stress and apoptosis in cisplatin-treated renal cells and hepatic I/R models via increased GSK3β phosphorylation and downstream HO-1 antioxidant enzyme expression.","method":"PLK2 overexpression/siRNA knockdown, GSK3β phosphorylation western blotting, HO-1 expression assays, ROS measurement, in vivo AKI/I-R mouse models","journal":"Experimental cell research / Journal of gastroenterology and hepatology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — gain/loss-of-function with kinase substrate (GSK3β) phosphorylation readout and functional consequence; replicated in two independent organ injury contexts","pmids":["35523306","39563073"],"is_preprint":false},{"year":2013,"finding":"Structure-guided crystallography of PLK2-inhibitor complexes enabled design of brain-penetrant, isoform-selective PLK2 inhibitors; oral administration of lead compounds significantly decreased Ser129 alpha-synuclein phosphorylation in rat brain, pharmacologically validating PLK2 as the dominant kinase for this modification in vivo.","method":"Crystal structure of PLK2-inhibitor complex, kinome selectivity profiling, in vivo rat brain pharmacodynamics","journal":"ChemMedChem","confidence":"High","confidence_rationale":"Tier 1 / Moderate — first reported PLK2-inhibitor crystal structures used for structure-guided design, with in vivo pharmacodynamic validation","pmids":["23794260"],"is_preprint":false},{"year":2012,"finding":"PLK2 phosphorylates HSP90, GRP-94, beta-tubulin, calumenin, and 14-3-3 epsilon in vitro; mass spectrometry identified the specific phosphosites generated by PLK2 on these substrates, revealing PLK2 substrate specificity determinants.","method":"Cell lysate kinase assay, 2D gel electrophoresis, mass spectrometry phosphosite identification","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro kinase assay with MS-based phosphosite identification on multiple substrates, single lab","pmids":["22828320"],"is_preprint":false},{"year":2025,"finding":"KLF5 transcription factor directly binds to the PLK2 promoter (by ChIP-qPCR and dual-luciferase reporter assay) and transcriptionally activates PLK2 expression; elevated PLK2 inhibits chondrocyte autophagy and contributes to osteoarthritis progression.","method":"ChIP-qPCR, dual-luciferase reporter assay, PLK2 knockdown, autophagy markers (Beclin-1, LC3), OA mouse model","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter binding demonstrated by ChIP and luciferase with functional autophagy readout, single lab","pmids":["41198759"],"is_preprint":false}],"current_model":"PLK2 (SNK) is a G1-phase serine/threonine polo-like kinase that is transcriptionally induced by p53 and neuronal activity; it phosphorylates a broad set of substrates including alpha-synuclein (Ser-129), CPAP/SAS-4 (centriole duplication), Fbxw7 (cyclin E stabilization), SQSTM1/p62 (aggrephagy), DCTN1 (autophagy flux), synGAP, RasGRF1, SPAR, N-cadherin, TAp73, mutant p53, NPM, and GSK3β; it is negatively regulated by CIB (Ca2+/integrin-binding protein) and SIRT1-mediated deacetylation/ubiquitination, and positively activated by DYRK1A-mediated phosphorylation at Ser358; through coordinated regulation of Ras and Rap GTPase regulators and AMPAR trafficking (via NSF disruption), PLK2 governs homeostatic synaptic plasticity, and through its centrosomal substrates it controls centriole duplication in a polo-box-dependent manner."},"narrative":{"mechanistic_narrative":"PLK2 (SNK) is a polo-like serine/threonine kinase that operates in two principal arenas: G1-phase control of the centrosome/cell cycle and activity-dependent homeostatic synaptic plasticity in neurons [PMID:12651910, PMID:10523297, PMID:12972611]. Its kinase activity is detectable in G1, depends on the catalytic Lys-108 and the activation residue Thr-236, and is restrained by an autoinhibitory C-terminus and by the calcium/integrin-binding protein CIB [PMID:12651910]. PLK2 is transcriptionally induced by p53, and its loss delays S-phase entry and slows proliferation in fibroblasts and embryos, linking it to a p53-dependent cell cycle/mitotic checkpoint program [PMID:12897130, PMID:12972611]. Through its polo-box domain PLK2 localizes to the mother centriole in early G1 and to both centrioles at S-phase onset, where it drives centriole duplication by phosphorylating CPAP/SAS-4 and destabilizing the SCF F-box protein Fbxw7 to permit cyclin E accumulation [PMID:20531387, PMID:19001868, PMID:22399798]; its abundance at the centrosome is gated by SIRT1-mediated deacetylation and ubiquitin-dependent degradation [PMID:30517871]. In neurons, PLK2 is targeted to dendrites following plasticity-inducing stimulation and enforces homeostatic synaptic downscaling by coordinately reprogramming Ras and Rap signaling — phosphorylation-dependent degradation of RasGRF1 and SPAR and activation of SynGAP and PDZGEF1 suppress Ras while activating Rap — and by a kinase-independent, NSF-binding mechanism that disrupts NSF-GluA2 to remove surface AMPARs [PMID:20802490, PMID:21382555, PMID:30049443]. PLK2 is the principal kinase phosphorylating alpha-synuclein at Ser-129 in the CNS, recognizing acidic residues flanking the site and engaging the alpha-synuclein N-terminus, and it additionally controls alpha-synuclein handling through autophagy via substrates such as SQSTM1/p62 and DCTN1 [PMID:19004816, PMID:24128992, PMID:22248692, PMID:39316746, PMID:39773002]. PLK2 activity is positively set by DYRK1A phosphorylation at Ser-358 and negatively set by CIB binding and SIRT1/SKP1-driven turnover [PMID:30517871, PMID:37387444, PMID:34234930].","teleology":[{"year":1999,"claim":"Established that PLK2 is not a constitutive housekeeping kinase but a stimulus-targeted neuronal protein, showing it is delivered to dendrites of activated neurons during synaptic plasticity and binds CIB through a conserved C-terminal domain.","evidence":"Immunolocalization in stimulated neurons plus yeast two-hybrid/binding assays for CIB","pmids":["10523297"],"confidence":"Medium","gaps":["Did not define which substrates underlie the dendritic function","Functional role of the CIB interaction not resolved"]},{"year":2003,"claim":"Defined the biochemical activation logic of PLK2 and a first negative regulator, placing its activity in G1 and identifying CIB as an inhibitor.","evidence":"Site-directed mutagenesis (T236E, K108), in vitro kinase assays, GFP localization to the MTOC, and Co-IP with CIB","pmids":["12651910"],"confidence":"High","gaps":["Physiological MTOC substrates not yet identified","Mechanism of C-terminal autoinhibition relief in cells unresolved"]},{"year":2003,"claim":"Connected PLK2 to the p53 network and to cell cycle progression, establishing it as a p53 transcriptional target with a mitotic-checkpoint and S-phase entry role.","evidence":"p53 target validation with siRNA knockdown plus paclitaxel/nocodazole death assays; gene-targeted KO mice with BrdU and growth assays","pmids":["12897130","12972611"],"confidence":"High","gaps":["Direct cell-cycle substrates not identified in these studies","Molecular basis of delayed S-phase entry unresolved"]},{"year":2008,"claim":"Identified the centrosome localization determinant and the first centriole substrate, linking PLK2 polo-box function to procentriole formation.","evidence":"Polo-box mutagenesis and immunofluorescence (centriole localization, PLK4 dependence); in vitro kinase assay and phospho-resistant CPAP mutant","pmids":["19001868","20531387"],"confidence":"Medium","gaps":["Hierarchy between PLK2 and PLK4 only partially mapped","How CPAP phosphorylation drives elongation mechanistically unresolved"]},{"year":2008,"claim":"Established PLK2 as the principal CNS kinase generating Ser-129 phosphorylated alpha-synuclein, the disease-associated modification.","evidence":"In vitro phosphorylation, pharmacological PLK inhibition, shRNA knockdown, and PLK2 KO mice measuring brain pSer-129","pmids":["19004816"],"confidence":"High","gaps":["Consequence of Ser-129 phosphorylation for synuclein aggregation not settled here","Identity of residual non-PLK2 kinase activity unknown"]},{"year":2010,"claim":"Revealed a kinase-independent PLK2 function in synaptic plasticity, showing PLK2 binds NSF to disrupt NSF-GluA2 and remove surface AMPARs.","evidence":"Reciprocal Co-IP, surface receptor and electrophysiology assays in rat hippocampal neurons, domain-mapping mutagenesis","pmids":["20802490"],"confidence":"High","gaps":["Structural basis of the non-polo-box NSF-binding motif undefined","How kinase-dependent and kinase-independent PLK2 activities are coordinated unresolved"]},{"year":2011,"claim":"Defined the mechanism by which PLK2 enforces homeostatic synaptic downscaling through coordinated Ras-suppression and Rap-activation, and linked this to memory.","evidence":"Genetic epistasis, phosphorylation and ubiquitin-proteasome assays on RasGRF1, SPAR, SynGAP, PDZGEF1; spine imaging and behavioral memory tasks","pmids":["21382555"],"confidence":"High","gaps":["Phosphosites on each GTPase regulator not all mapped here","Whether all four substrates are phosphorylated in the same synapse unresolved"]},{"year":2011,"claim":"Extended PLK2 into oncogenic p53 biology, showing it phosphorylates mutant p53 to potentiate its transcriptional activity in an autoregulatory loop.","evidence":"Co-IP, kinase assay, transcriptional reporter assays, siRNA knockdown","pmids":["22134238"],"confidence":"Medium","gaps":["Phosphosite on mutant p53 not defined","In vivo relevance to tumor phenotypes untested here"]},{"year":2012,"claim":"Expanded the centriole-duplication mechanism by showing PLK2 destabilizes Fbxw7 to drive cyclin E accumulation, and quantitatively defined PLK2 reshaping of SynGAP GTPase selectivity.","evidence":"In vitro kinase assays with phosphosite mapping (Fbxw7 S176; SynGAP by MS), Co-IP, GTPase activity measurements, centriole counting","pmids":["22399798","30049443"],"confidence":"High","gaps":["Whether Fbxw7 destabilization contributes to centriole amplification in vivo unresolved","Integration of PLK2 and CDK5 SynGAP phosphorylation in intact synapses not tested"]},{"year":2012,"claim":"Defined the substrate-recognition determinants of PLK2 on alpha-synuclein and broadened its in vitro substrate repertoire.","evidence":"In vitro kinase assays with peptide substitution (Glu-126/Glu-131), comparison with CK2; cell-lysate kinase assay with MS phosphosite mapping (HSP90, GRP-94, beta-tubulin, calumenin, 14-3-3 epsilon); yeast Cdc5/Rho1 genetics","pmids":["22248692","22828320","22988096"],"confidence":"Medium","gaps":["In-cell relevance of the broad in vitro substrate set unverified","Functional consequence of HSP90/tubulin/14-3-3 phosphorylation unknown"]},{"year":2013,"claim":"Pharmacologically and structurally validated PLK2 as the dominant in vivo Ser-129 alpha-synuclein kinase, enabling selective inhibitor development.","evidence":"PLK2-inhibitor crystal structures with kinome selectivity and in vivo rat brain pharmacodynamics; KO/heterozygote dosage study with BI 2536 epistasis","pmids":["23794260","24128992"],"confidence":"High","gaps":["Identity of the residual non-PLK2 Ser-129 kinase unresolved","Therapeutic consequence of reducing pSer-129 not established here"]},{"year":2014,"claim":"Demonstrated an in vivo tissue-morphogenesis role, showing Plk2 controls mitotic spindle orientation and epithelial polarity in the mammary gland.","evidence":"Plk2 KO mice with spindle orientation imaging and mammary morphology/proliferation analysis","pmids":["24598160"],"confidence":"Medium","gaps":["Spindle-orientation substrate not identified","Mechanistic link to centriole substrates unresolved"]},{"year":2015,"claim":"Positioned PLK2 within centrosome-amplification and tumor-suppressor signaling pathways through NPM/ROCK2/PLK4 and TAp73 phosphorylation.","evidence":"Centrosome amplification epistasis/rescue assays; in vitro kinase assay and Co-IP for TAp73 S48 with cisplatin functional assays","pmids":["25590559","26625870"],"confidence":"Medium","gaps":["Direct NPM phosphosite and ROCK2 activation mechanism partly unresolved","TAp73 axis tested in limited cell contexts"]},{"year":2017,"claim":"Linked PLK2 to alpha-synuclein clearance, showing PLK2 promotes macroautophagic co-degradation of phospho-synuclein and itself.","evidence":"Genetic/pharmacological autophagy inhibition, domain mapping, ubiquitination assays, Co-IP","pmids":["28154193"],"confidence":"Medium","gaps":["Autophagy receptor mediating PLK2/synuclein clearance not defined here","Reconciliation with later flux-blocking role unresolved"]},{"year":2018,"claim":"Defined the cell-cycle-timed PTM circuit controlling PLK2 abundance, with AURKA-phosphorylated SIRT1 deacetylating PLK2 to license its ubiquitin-dependent turnover and centrosomal accumulation.","evidence":"Co-IP, acetylation/ubiquitination/deacetylase assays, cell-cycle synchronization, centrosome imaging","pmids":["30517871"],"confidence":"High","gaps":["E3 ligase acting on deacetylated PLK2 not identified","Acetylated lysines on PLK2 not fully mapped"]},{"year":2021,"claim":"Identified SKP1-mediated ubiquitination as an additional route of PLK2 degradation relevant to alpha-synuclein aggregation.","evidence":"Co-IP, in vitro ubiquitination assay, miRNA target luciferase reporter","pmids":["34234930"],"confidence":"Medium","gaps":["Single lab with modest methodological depth; not independently confirmed","Relationship to SIRT1-dependent turnover pathway unresolved"]},{"year":2023,"claim":"Identified DYRK1A as a positive upstream activator of PLK2 (Ser-358 phosphorylation increasing stability and activity) and added N-cadherin as a synaptic substrate, broadening upstream control and downstream effects.","evidence":"Co-IP and in vitro kinase assays with phosphosite mutagenesis; N-cadherin kinase/Co-IP and proteolytic processing assays with synaptic imaging","pmids":["37387444","37654026"],"confidence":"Medium","gaps":["Whether DYRK1A control operates in neurons as well as cancer cells untested","N-cadherin axis from a single lab"]},{"year":2024,"claim":"Expanded PLK2 into proteostasis and stress-protection roles via SQSTM1/p62 S349, GSK3beta inactivation, and KLF5-driven transcription, connecting PLK2 to aggrephagy, antioxidant signaling, and autophagy suppression.","evidence":"In vitro kinase assays with phosphosite mutagenesis, Co-IP, aggregate-formation assays; gain/loss-of-function with GSK3beta/HO-1/ROS readouts in two organ-injury models; ChIP-qPCR and luciferase for KLF5","pmids":["39316746","35523306","39563073","41198759"],"confidence":"Medium","gaps":["GSK3beta and KLF5 axes are largely single-context","How aggrephagy-promoting and flux-blocking roles coexist unresolved"]},{"year":2025,"claim":"Revealed a kinase-dependent but Ser-129-independent mechanism by which PLK2 drives synuclein pathology, phosphorylating DCTN1 (S1098) to block autophagosome-lysosome fusion and impair flux.","evidence":"In vitro kinase assay with phosphosite ID, autophagy flux/fusion imaging (LC3, LAMP1), in vivo mouse model with genetic PLK2 suppression","pmids":["39773002"],"confidence":"High","gaps":["How the same kinase both clears (macroautophagy) and blocks (flux) synuclein not reconciled","Whether DCTN1 phosphorylation occurs in human disease tissue untested"]},{"year":2026,"claim":"Placed PLK2 within a FAM117B/DYRK1A signaling axis promoting colorectal cancer phenotypes, extending the DYRK1A-PLK2 regulatory module to a new tumor context.","evidence":"Co-IP, IP-kinase assay, knockdown/overexpression rescue, in vivo xenograft","pmids":["41504297"],"confidence":"Medium","gaps":["Direct PLK2 substrates driving CRC phenotypes not identified","Single-lab cancer-context finding"]},{"year":null,"claim":"How PLK2's distinct functional modes — kinase-dependent centriole/synaptic substrate phosphorylation, kinase-independent NSF disruption, and opposing pro- and anti-autophagic actions on alpha-synuclein — are selected within a single cell remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model integrating cell-cycle versus synaptic substrate selection","No structural basis distinguishing polo-box-dependent versus NSF-binding modes","Reconciliation of synuclein clearance versus flux-blocking roles missing"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[4,5,9,12,23,24,30]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[1,4,5,9,12]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[1]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[7,8]}],"localization":[{"term_id":"GO:0005815","term_label":"microtubule organizing center","supporting_discovery_ids":[1,6,19]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[2]}],"pathway":[{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[0,3,6,9,19]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[2,7,8,25]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[16,23,24,31]},{"term_id":"R-HSA-1852241","term_label":"Organelle biogenesis and maintenance","supporting_discovery_ids":[5,6,20]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[8,10,12,28]}],"complexes":[],"partners":["CIB1","NSF","FBXW7","SIRT1","DYRK1A","SKP1","TSC1","NPM1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9NYY3","full_name":"Serine/threonine-protein kinase PLK2","aliases":["Polo-like kinase 2","PLK-2","hPlk2","Serine/threonine-protein kinase SNK","hSNK","Serum-inducible kinase"],"length_aa":685,"mass_kda":78.2,"function":"Tumor suppressor serine/threonine-protein kinase involved in synaptic plasticity, centriole duplication and G1/S phase transition. Polo-like kinases act by binding and phosphorylating proteins that are already phosphorylated on a specific motif recognized by the POLO box domains. Phosphorylates CPAP, NPM1, RAPGEF2, RASGRF1, SNCA, SIPA1L1 and SYNGAP1. Plays a key role in synaptic plasticity and memory by regulating the Ras and Rap protein signaling: required for overactivity-dependent spine remodeling by phosphorylating the Ras activator RASGRF1 and the Rap inhibitor SIPA1L1 leading to their degradation by the proteasome. Conversely, phosphorylates the Rap activator RAPGEF2 and the Ras inhibitor SYNGAP1, promoting their activity. Also regulates synaptic plasticity independently of kinase activity, via its interaction with NSF that disrupts the interaction between NSF and the GRIA2 subunit of AMPARs, leading to a rapid rundown of AMPAR-mediated current that occludes long term depression. Required for procentriole formation and centriole duplication by phosphorylating CPAP and NPM1, respectively. Its induction by p53/TP53 suggests that it may participate in the mitotic checkpoint following stress","subcellular_location":"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole; Cell projection, dendrite","url":"https://www.uniprot.org/uniprotkb/Q9NYY3/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PLK2","classification":"Not Classified","n_dependent_lines":6,"n_total_lines":1208,"dependency_fraction":0.004966887417218543},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PLK2","total_profiled":1310},"omim":[{"mim_id":"607023","title":"POLO-LIKE KINASE 2; PLK2","url":"https://www.omim.org/entry/607023"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Mitochondria","reliability":"Approved"},{"location":"Cytosol","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/PLK2"},"hgnc":{"alias_symbol":["SNK"],"prev_symbol":[]},"alphafold":{"accession":"Q9NYY3","domains":[{"cath_id":"3.30.200.20","chopping":"71-159","consensus_level":"high","plddt":93.404,"start":71,"end":159},{"cath_id":"1.10.510.10","chopping":"166-343","consensus_level":"high","plddt":94.128,"start":166,"end":343},{"cath_id":"3.30.1120.30","chopping":"450-681","consensus_level":"high","plddt":83.6137,"start":450,"end":681}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NYY3","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NYY3-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NYY3-F1-predicted_aligned_error_v6.png","plddt_mean":75.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PLK2","jax_strain_url":"https://www.jax.org/strain/search?query=PLK2"},"sequence":{"accession":"Q9NYY3","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NYY3.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NYY3/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NYY3"}},"corpus_meta":[{"pmid":"12897130","id":"PMC_12897130","title":"Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12897130","citation_count":198,"is_preprint":false},{"pmid":"19004816","id":"PMC_19004816","title":"Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19004816","citation_count":193,"is_preprint":false},{"pmid":"10523297","id":"PMC_10523297","title":"The polo-like protein kinases Fnk and Snk associate with a Ca(2+)- and integrin-binding protein and are regulated dynamically with synaptic plasticity.","date":"1999","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10523297","citation_count":176,"is_preprint":false},{"pmid":"12972611","id":"PMC_12972611","title":"Role of Plk2 (Snk) in mouse development and cell proliferation.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12972611","citation_count":133,"is_preprint":false},{"pmid":"16160013","id":"PMC_16160013","title":"Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16160013","citation_count":106,"is_preprint":false},{"pmid":"21382555","id":"PMC_21382555","title":"Requirement for Plk2 in orchestrated ras and rap signaling, homeostatic structural plasticity, and memory.","date":"2011","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/21382555","citation_count":83,"is_preprint":false},{"pmid":"12651910","id":"PMC_12651910","title":"The serum-inducible protein kinase Snk is a G1 phase polo-like kinase that is inhibited by the calcium- and integrin-binding protein CIB.","date":"2003","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/12651910","citation_count":69,"is_preprint":false},{"pmid":"27423313","id":"PMC_27423313","title":"Plk2 promotes tumor growth and inhibits apoptosis by targeting Fbxw7/Cyclin E in colorectal cancer.","date":"2016","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/27423313","citation_count":68,"is_preprint":false},{"pmid":"30099283","id":"PMC_30099283","title":"Lead, cadmium, arsenic, and mercury combined exposure disrupted synaptic homeostasis through activating the Snk-SPAR pathway.","date":"2018","source":"Ecotoxicology and environmental safety","url":"https://pubmed.ncbi.nlm.nih.gov/30099283","citation_count":65,"is_preprint":false},{"pmid":"22399798","id":"PMC_22399798","title":"Plk2 regulates centriole duplication through phosphorylation-mediated degradation of Fbxw7 (human Cdc4).","date":"2012","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/22399798","citation_count":63,"is_preprint":false},{"pmid":"17150265","id":"PMC_17150265","title":"Evaluation of Rana snk esculenta blood cell response to chemical stressors in the environment during the larval and adult phases.","date":"2006","source":"Aquatic toxicology (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/17150265","citation_count":63,"is_preprint":false},{"pmid":"25239093","id":"PMC_25239093","title":"MicroRNA-27a promotes proliferation and suppresses apoptosis by targeting PLK2 in laryngeal carcinoma.","date":"2014","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25239093","citation_count":62,"is_preprint":false},{"pmid":"22134238","id":"PMC_22134238","title":"Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop.","date":"2011","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/22134238","citation_count":61,"is_preprint":false},{"pmid":"20802490","id":"PMC_20802490","title":"Plk2 attachment to NSF induces homeostatic removal of GluA2 during chronic overexcitation.","date":"2010","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/20802490","citation_count":60,"is_preprint":false},{"pmid":"20531387","id":"PMC_20531387","title":"PLK2 phosphorylation is critical for CPAP function in procentriole formation during the centrosome cycle.","date":"2010","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/20531387","citation_count":57,"is_preprint":false},{"pmid":"20054236","id":"PMC_20054236","title":"The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions.","date":"2009","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/20054236","citation_count":56,"is_preprint":false},{"pmid":"23266469","id":"PMC_23266469","title":"Celastrol suppresses breast cancer MCF-7 cell viability via the AMP-activated protein kinase (AMPK)-induced p53-polo like kinase 2 (PLK-2) pathway.","date":"2012","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/23266469","citation_count":54,"is_preprint":false},{"pmid":"17912033","id":"PMC_17912033","title":"Replication stress, defective S-phase checkpoint and increased death in Plk2-deficient human cancer cells.","date":"2007","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/17912033","citation_count":53,"is_preprint":false},{"pmid":"19001868","id":"PMC_19001868","title":"Plk2 regulated centriole duplication is dependent on its localization to the centrioles and a functional polo-box domain.","date":"2008","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/19001868","citation_count":52,"is_preprint":false},{"pmid":"21402713","id":"PMC_21402713","title":"Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21402713","citation_count":47,"is_preprint":false},{"pmid":"31697645","id":"PMC_31697645","title":"Neuroprotective effects of protocatechuic aldehyde through PLK2/p-GSK3β/Nrf2 signaling pathway in both in vivo and in vitro models of Parkinson's disease.","date":"2019","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/31697645","citation_count":44,"is_preprint":false},{"pmid":"24128992","id":"PMC_24128992","title":"In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain.","date":"2013","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/24128992","citation_count":44,"is_preprint":false},{"pmid":"24969300","id":"PMC_24969300","title":"Mir-126 inhibits growth of SGC-7901 cells by synergistically targeting the oncogenes PI3KR2 and Crk, and the tumor suppressor PLK2.","date":"2014","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24969300","citation_count":41,"is_preprint":false},{"pmid":"22988096","id":"PMC_22988096","title":"α-Synuclein disrupts stress signaling by inhibiting polo-like kinase Cdc5/Plk2.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22988096","citation_count":36,"is_preprint":false},{"pmid":"23794260","id":"PMC_23794260","title":"Selective and brain-permeable polo-like kinase-2 (Plk-2) inhibitors that reduce α-synuclein phosphorylation in rat brain.","date":"2013","source":"ChemMedChem","url":"https://pubmed.ncbi.nlm.nih.gov/23794260","citation_count":35,"is_preprint":false},{"pmid":"21340720","id":"PMC_21340720","title":"Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions.","date":"2011","source":"Annals of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/21340720","citation_count":34,"is_preprint":false},{"pmid":"22828320","id":"PMC_22828320","title":"Investigation on PLK2 and PLK3 substrate recognition.","date":"2012","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/22828320","citation_count":31,"is_preprint":false},{"pmid":"28154193","id":"PMC_28154193","title":"Dissecting the Molecular Pathway Involved in PLK2 Kinase-mediated α-Synuclein-selective Autophagic Degradation.","date":"2017","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28154193","citation_count":30,"is_preprint":false},{"pmid":"24598160","id":"PMC_24598160","title":"Plk2 regulates mitotic spindle orientation and mammary gland development.","date":"2014","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24598160","citation_count":30,"is_preprint":false},{"pmid":"33176854","id":"PMC_33176854","title":"Loss of PLK2 induces acquired resistance to temozolomide in GBM via activation of notch signaling.","date":"2020","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/33176854","citation_count":29,"is_preprint":false},{"pmid":"19506885","id":"PMC_19506885","title":"Identification of urine PLK2 as a marker of bladder tumors by proteomic analysis.","date":"2009","source":"World journal of urology","url":"https://pubmed.ncbi.nlm.nih.gov/19506885","citation_count":27,"is_preprint":false},{"pmid":"30517871","id":"PMC_30517871","title":"Histone Deacetylase SIRT1 Targets Plk2 to Regulate Centriole Duplication.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30517871","citation_count":26,"is_preprint":false},{"pmid":"30897343","id":"PMC_30897343","title":"Nrf2-lncRNA controls cell fate by modulating p53-dependent Nrf2 activation as an miRNA sponge for Plk2 and p21cip1.","date":"2019","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/30897343","citation_count":26,"is_preprint":false},{"pmid":"28655909","id":"PMC_28655909","title":"PLK2 Plays an Essential Role in High D-Glucose-Induced Apoptosis, ROS Generation and Inflammation in Podocytes.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28655909","citation_count":26,"is_preprint":false},{"pmid":"36552896","id":"PMC_36552896","title":"Lactobacillus salivarius SNK-6 Regulates Liver Lipid Metabolism Partly via the miR-130a-5p/MBOAT2 Pathway in a NAFLD Model of Laying Hens.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36552896","citation_count":26,"is_preprint":false},{"pmid":"22248692","id":"PMC_22248692","title":"Superiority of PLK-2 as α-synuclein phosphorylating agent relies on unique specificity determinants.","date":"2012","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/22248692","citation_count":25,"is_preprint":false},{"pmid":"11696980","id":"PMC_11696980","title":"Identification of the human homologue of the early-growth response gene Snk, encoding a serum-inducible kinase.","date":"2001","source":"DNA sequence : the journal of DNA sequencing and mapping","url":"https://pubmed.ncbi.nlm.nih.gov/11696980","citation_count":23,"is_preprint":false},{"pmid":"23522834","id":"PMC_23522834","title":"Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors.","date":"2013","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/23522834","citation_count":23,"is_preprint":false},{"pmid":"22870256","id":"PMC_22870256","title":"Hormonal induction of polo-like kinases (Plks) and impact of Plk2 on cell cycle progression in the rat ovary.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22870256","citation_count":21,"is_preprint":false},{"pmid":"29448085","id":"PMC_29448085","title":"Plk2 Loss Commonly Occurs in Colorectal Carcinomas but not Adenomas: Relationship to mTOR Signaling.","date":"2018","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/29448085","citation_count":18,"is_preprint":false},{"pmid":"23850969","id":"PMC_23850969","title":"Prenatal stress increased Snk Polo-like kinase 2, SCF β-TrCP ubiquitin ligase and ubiquitination of SPAR in the hippocampus of the offspring at adulthood.","date":"2013","source":"International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/23850969","citation_count":18,"is_preprint":false},{"pmid":"17706945","id":"PMC_17706945","title":"Involvement of the Snk-SPAR pathway in glutamate-induced excitotoxicity in cultured hippocampal neurons.","date":"2007","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/17706945","citation_count":18,"is_preprint":false},{"pmid":"31902745","id":"PMC_31902745","title":"Plk2 Regulated by miR-128 Induces Ischemia-Reperfusion Injury in Cardiac Cells.","date":"2019","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/31902745","citation_count":17,"is_preprint":false},{"pmid":"29180226","id":"PMC_29180226","title":"Microwave radiation leading to shrinkage of dendritic spines in hippocampal neurons mediated by SNK-SPAR pathway.","date":"2017","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/29180226","citation_count":17,"is_preprint":false},{"pmid":"34047419","id":"PMC_34047419","title":"PLK2 protects retinal ganglion cells from oxidative stress by potentiating Nrf2 signaling via GSK-3β.","date":"2021","source":"Journal of biochemical and molecular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/34047419","citation_count":16,"is_preprint":false},{"pmid":"35156101","id":"PMC_35156101","title":"Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics.","date":"2021","source":"Cancer research communications","url":"https://pubmed.ncbi.nlm.nih.gov/35156101","citation_count":16,"is_preprint":false},{"pmid":"35889188","id":"PMC_35889188","title":"Lactobacillus salivarius SNK-6 Activates Intestinal Mucosal Immune System by Regulating Cecal Microbial Community Structure in Laying Hens.","date":"2022","source":"Microorganisms","url":"https://pubmed.ncbi.nlm.nih.gov/35889188","citation_count":16,"is_preprint":false},{"pmid":"26762835","id":"PMC_26762835","title":"Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).","date":"2015","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26762835","citation_count":16,"is_preprint":false},{"pmid":"29366414","id":"PMC_29366414","title":"The Acidophilic Kinases PLK2 and PLK3: Structure, Substrate Targeting and Inhibition.","date":"2018","source":"Current protein & peptide science","url":"https://pubmed.ncbi.nlm.nih.gov/29366414","citation_count":15,"is_preprint":false},{"pmid":"37980753","id":"PMC_37980753","title":"Effect of Lactobacillus salivarius SNK-6 on egg quality, intestinal morphology, and cecal microbial community of laying hens.","date":"2023","source":"Poultry science","url":"https://pubmed.ncbi.nlm.nih.gov/37980753","citation_count":15,"is_preprint":false},{"pmid":"26625870","id":"PMC_26625870","title":"PLK2 phosphorylates and inhibits enriched TAp73 in human osteosarcoma cells.","date":"2015","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26625870","citation_count":14,"is_preprint":false},{"pmid":"15531183","id":"PMC_15531183","title":"Erythrocytic sorbitol contents in diabetic patients correlate with blood aldose reductase protein contents and plasma glucose levels, and are normalized by the potent aldose reductase inhibitor fidarestat (SNK-860).","date":"2004","source":"Journal of diabetes and its complications","url":"https://pubmed.ncbi.nlm.nih.gov/15531183","citation_count":14,"is_preprint":false},{"pmid":"30049443","id":"PMC_30049443","title":"Phosphorylation of synaptic GTPase-activating protein (synGAP) by polo-like kinase (Plk2) alters the ratio of its GAP activity toward HRas, Rap1 and Rap2 GTPases.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30049443","citation_count":13,"is_preprint":false},{"pmid":"21776418","id":"PMC_21776418","title":"Plk2 Raps up Ras to subdue synapses.","date":"2011","source":"Small GTPases","url":"https://pubmed.ncbi.nlm.nih.gov/21776418","citation_count":12,"is_preprint":false},{"pmid":"32180729","id":"PMC_32180729","title":"LY354740 Reduces Extracellular Glutamate Concentration, Inhibits Phosphorylation of Fyn/NMDARs, and Expression of PLK2/pS129 α-Synuclein in Mice Treated With Acute or Sub-Acute MPTP.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32180729","citation_count":12,"is_preprint":false},{"pmid":"37387444","id":"PMC_37387444","title":"DYRK1A-mediated PLK2 phosphorylation regulates the proliferation and invasion of glioblastoma cells.","date":"2023","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37387444","citation_count":11,"is_preprint":false},{"pmid":"38282412","id":"PMC_38282412","title":"Isolation and Proteomic Analysis of Extracellular Vesicles from Lactobacillus salivarius SNK-6.","date":"2023","source":"Journal of microbiology and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/38282412","citation_count":11,"is_preprint":false},{"pmid":"35905928","id":"PMC_35905928","title":"Inhibition of PLK2 activity affects APP and tau pathology and improves synaptic content in a sex-dependent manner in a 3xTg mouse model of Alzheimer's disease.","date":"2022","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/35905928","citation_count":11,"is_preprint":false},{"pmid":"20146300","id":"PMC_20146300","title":"Role of the SNK-SPAR pathway in the development of Alzheimer's disease.","date":"2010","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/20146300","citation_count":11,"is_preprint":false},{"pmid":"32878237","id":"PMC_32878237","title":"Targeting Adaptive IRE1α Signaling and PLK2 in Multiple Myeloma: Possible Anti-Tumor Mechanisms of KIRA8 and Nilotinib.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32878237","citation_count":11,"is_preprint":false},{"pmid":"18679602","id":"PMC_18679602","title":"Effects of Zibu Piyin recipe on SNK-SPAR pathway in neuron injury induced by glutamate.","date":"2008","source":"Chinese journal of integrative medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18679602","citation_count":11,"is_preprint":false},{"pmid":"30638284","id":"PMC_30638284","title":"Downregulated miR-27b promotes keratinocyte proliferation by targeting PLK2 in oral lichen planus.","date":"2019","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30638284","citation_count":11,"is_preprint":false},{"pmid":"27687332","id":"PMC_27687332","title":"Complicated function of dopamine in Aβ-related neurotoxicity: Dual interactions with Tyr10 and SNK(26-28) of Aβ.","date":"2016","source":"Journal of inorganic biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27687332","citation_count":11,"is_preprint":false},{"pmid":"25590559","id":"PMC_25590559","title":"Functional relationship among PLK2, PLK4 and ROCK2 to induce centrosome amplification.","date":"2015","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/25590559","citation_count":10,"is_preprint":false},{"pmid":"23466428","id":"PMC_23466428","title":"Pharmacological inhibition of polo like kinase 2 (PLK2) does not cause chromosomal damage or result in the formation of micronuclei.","date":"2013","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23466428","citation_count":10,"is_preprint":false},{"pmid":"26307252","id":"PMC_26307252","title":"Tools to discriminate between targets of CK2 vs PLK2/PLK3 acidophilic kinases.","date":"2012","source":"BioTechniques","url":"https://pubmed.ncbi.nlm.nih.gov/26307252","citation_count":10,"is_preprint":false},{"pmid":"34060415","id":"PMC_34060415","title":"Circular RNA 0102049 suppresses the progression of osteosarcoma through modulating miR-520g-3p/PLK2 axis.","date":"2021","source":"Bioengineered","url":"https://pubmed.ncbi.nlm.nih.gov/34060415","citation_count":9,"is_preprint":false},{"pmid":"28696012","id":"PMC_28696012","title":"Inhibition of SNK-SPAR signaling pathway promotes the restoration of motor function in a rat model of ischemic stroke.","date":"2017","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28696012","citation_count":9,"is_preprint":false},{"pmid":"35523306","id":"PMC_35523306","title":"PLK2 targets GSK3β to protect against cisplatin-induced acute kidney injury.","date":"2022","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/35523306","citation_count":8,"is_preprint":false},{"pmid":"34410453","id":"PMC_34410453","title":"Systemic mesalazine treatment prevents spontaneous skin fibrosis in PLK2-deficient mice.","date":"2021","source":"Naunyn-Schmiedeberg's archives of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34410453","citation_count":8,"is_preprint":false},{"pmid":"34234930","id":"PMC_34234930","title":"miR-101-3p Contributes to α-Synuclein Aggregation in Neural Cells through the miR-101-3p/SKP1/PLK2 Pathway.","date":"2021","source":"Journal of healthcare engineering","url":"https://pubmed.ncbi.nlm.nih.gov/34234930","citation_count":8,"is_preprint":false},{"pmid":"7648800","id":"PMC_7648800","title":"Effects of glucose and SNK-860, an aldose reductase inhibitor, on the polyol pathway and chemiluminescence response of human neutrophils in vitro.","date":"1995","source":"Diabetic medicine : a journal of the British Diabetic Association","url":"https://pubmed.ncbi.nlm.nih.gov/7648800","citation_count":8,"is_preprint":false},{"pmid":"10447652","id":"PMC_10447652","title":"Inhibitory effect of orally administered aldose reductase inhibitor SNK-860 on corneal polyol accumulation in galactose-fed rats.","date":"1999","source":"Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie","url":"https://pubmed.ncbi.nlm.nih.gov/10447652","citation_count":8,"is_preprint":false},{"pmid":"25338102","id":"PMC_25338102","title":"Identification of the PLK2-dependent phosphopeptidome by quantitative proteomics [corrected].","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25338102","citation_count":7,"is_preprint":false},{"pmid":"21362453","id":"PMC_21362453","title":"Repeated carbenoxolone injections during late pregnancy alter Snk-SPAR and PSD-95 expression in the hippocampus of rat pups.","date":"2011","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/21362453","citation_count":7,"is_preprint":false},{"pmid":"39316746","id":"PMC_39316746","title":"PLK2-mediated phosphorylation of SQSTM1 S349 promotes aggregation of polyubiquitinated proteins upon proteasomal dysfunction.","date":"2024","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/39316746","citation_count":6,"is_preprint":false},{"pmid":"28400058","id":"PMC_28400058","title":"The SNK and SPAR signaling pathway changes in hippocampal neurons treated with amyloid-beta peptide in vitro.","date":"2017","source":"Neuropeptides","url":"https://pubmed.ncbi.nlm.nih.gov/28400058","citation_count":6,"is_preprint":false},{"pmid":"40805135","id":"PMC_40805135","title":"Supercharged Natural Killer (sNK) Cells Inhibit Melanoma Tumor Progression and Restore Endogenous NK Cell Function in Humanized BLT Mice.","date":"2025","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/40805135","citation_count":6,"is_preprint":false},{"pmid":"28069584","id":"PMC_28069584","title":"Role of norepinephrine in Aβ-related neurotoxicity: dual interactions with Tyr10 and SNK(26-28) of Aβ.","date":"2017","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/28069584","citation_count":6,"is_preprint":false},{"pmid":"21497903","id":"PMC_21497903","title":"Response of renal parenchyma and interstitium of Rana snk. esculenta to environmental pollution.","date":"2011","source":"Ecotoxicology and environmental safety","url":"https://pubmed.ncbi.nlm.nih.gov/21497903","citation_count":6,"is_preprint":false},{"pmid":"32231136","id":"PMC_32231136","title":"Proteome Analysis in a Mammalian Cell line Reveals that PLK2 is Involved in Avian Metapneumovirus Type C (aMPV/C)-Induced Apoptosis.","date":"2020","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/32231136","citation_count":5,"is_preprint":false},{"pmid":"39773002","id":"PMC_39773002","title":"PLK2 disrupts autophagic flux to promote SNCA/α-synuclein pathology.","date":"2025","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/39773002","citation_count":4,"is_preprint":false},{"pmid":"37654026","id":"PMC_37654026","title":"Plk2 promotes synaptic destabilization through disruption of N-cadherin adhesion complexes during homeostatic adaptation to hyperexcitation.","date":"2023","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37654026","citation_count":4,"is_preprint":false},{"pmid":"38880050","id":"PMC_38880050","title":"The protective effects of Lactobacillus SNK-6 on growth, organ health, and intestinal function in geese exposed to low concentration Aflatoxin B1.","date":"2024","source":"Poultry science","url":"https://pubmed.ncbi.nlm.nih.gov/38880050","citation_count":4,"is_preprint":false},{"pmid":"39563073","id":"PMC_39563073","title":"PLK2 inhibited oxidative stress and ameliorated hepatic ischemia-reperfusion injury through phosphorylating GSK3β.","date":"2024","source":"Journal of gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/39563073","citation_count":3,"is_preprint":false},{"pmid":"39498012","id":"PMC_39498012","title":"Pharmacological inhibition of PLK2 kinase activity mitigates cognitive decline but aggravates APP pathology in a sex-dependent manner in APP/PS1 mouse model of Alzheimer's disease.","date":"2024","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/39498012","citation_count":3,"is_preprint":false},{"pmid":"41019094","id":"PMC_41019094","title":"PLK2 as a key regulator of glycolysis and immune dysregulation in polycystic ovary syndrome.","date":"2025","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/41019094","citation_count":2,"is_preprint":false},{"pmid":"38176950","id":"PMC_38176950","title":"Icariin Inhibits Overexpression and Aggregation of α-Synuclein in A53T α-Synuclein Transgenic Mice by Regulating Parkin and PLK2.","date":"2023","source":"Journal of integrative neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/38176950","citation_count":2,"is_preprint":false},{"pmid":"39927502","id":"PMC_39927502","title":"A potential tumor suppressor role of PLK2 in glioblastoma.","date":"2025","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/39927502","citation_count":2,"is_preprint":false},{"pmid":"36316110","id":"PMC_36316110","title":"PLK2 Single Nucleotide Variant in Gastric Cancer Patients Affects miR-23b-5p Binding.","date":"2022","source":"Journal of gastric cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36316110","citation_count":2,"is_preprint":false},{"pmid":"36008099","id":"PMC_36008099","title":"Acute MPTP treatment decreases dendritic spine density of striatal medium spiny neurons via SNK-SPAR pathway in C57BL/6 mice.","date":"2022","source":"Synapse (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/36008099","citation_count":2,"is_preprint":false},{"pmid":"39611994","id":"PMC_39611994","title":"Rational design of potent phosphopeptide binders to endocrine Snk PBD domain by integrating machine learning optimization, molecular dynamics simulation, binding energetics rescoring, and in vitro affinity assay.","date":"2024","source":"European biophysics journal : EBJ","url":"https://pubmed.ncbi.nlm.nih.gov/39611994","citation_count":2,"is_preprint":false},{"pmid":"11385299","id":"PMC_11385299","title":"Utilization of Drosophila eye to probe the functions of two mammalian serine/threonine kinases, Snk and HsHPK.","date":"2001","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/11385299","citation_count":2,"is_preprint":false},{"pmid":"31839047","id":"PMC_31839047","title":"[MiR-30b Regulates the Cisplatin-Resistance of Human NK/T Cell Lypnphoma Cell Lines SNK-6 and YTS by Targeting the CCL22].","date":"2019","source":"Zhongguo shi yan xue ye xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/31839047","citation_count":1,"is_preprint":false},{"pmid":"24332050","id":"PMC_24332050","title":"[Effect of doxorubicin on TRAIL resistance and TRAIL receptor expression in lymphoma cell line SNK-6 cells].","date":"2013","source":"Zhonghua zhong liu za zhi [Chinese journal of oncology]","url":"https://pubmed.ncbi.nlm.nih.gov/24332050","citation_count":1,"is_preprint":false},{"pmid":"41504297","id":"PMC_41504297","title":"FAM117B Promotes Colorectal Cancer Progression by Enhancing DYRK1A-mediated Phosphorylation of PLK2.","date":"2026","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/41504297","citation_count":1,"is_preprint":false},{"pmid":"40080197","id":"PMC_40080197","title":"Decreased PLK2 promotes atrial fibrillation in diabetic mice through Nrf2/HO-1 pathway.","date":"2025","source":"Acta diabetologica","url":"https://pubmed.ncbi.nlm.nih.gov/40080197","citation_count":0,"is_preprint":false},{"pmid":"41237696","id":"PMC_41237696","title":"BI-2536 attenuates IPF progression by inhibiting the PLK2/JNK/SP1 Signaling pathway in AT2 cells.","date":"2025","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/41237696","citation_count":0,"is_preprint":false},{"pmid":"41530586","id":"PMC_41530586","title":"Abnormal PLK2 expression is associated with specific subtypes and may help risk stratification in acute myeloid leukemia.","date":"2026","source":"Discover oncology","url":"https://pubmed.ncbi.nlm.nih.gov/41530586","citation_count":0,"is_preprint":false},{"pmid":"41198759","id":"PMC_41198759","title":"KLF5 aggravates osteoarthritis progression by inhibiting chondrocyte autophagy via transcriptional activation of PLK2.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/41198759","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51688,"output_tokens":7967,"usd":0.137285,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17462,"output_tokens":6407,"usd":0.123743,"stage2_stop_reason":"end_turn"},"total_usd":0.261028,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"PLK2/Snk is a direct transcriptional target of p53; its kinase activity is negatively regulated by its C-terminus, and siRNA-mediated silencing in the presence of paclitaxel or nocodazole significantly increased apoptosis occurring in mitotic cells, indicating a p53-dependent mitotic checkpoint role.\",\n      \"method\": \"siRNA knockdown, mutagenesis, cell death assays in mitotic cells\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown with defined mitotic phenotype and mutagenesis, single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"12897130\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Endogenous Snk/PLK2 kinase activity is detected in G1 phase; substitution of Thr-236 with glutamate increases kinase activity ~10-fold while Lys-108 substitution abolishes activity; GFP-C-Snk localizes to the microtubule organizing center in a polo-box-dependent manner; calcium- and integrin-binding protein CIB co-immunoprecipitates with Snk and inhibits its kinase activity, functioning as a negative regulator.\",\n      \"method\": \"Site-directed mutagenesis, kinase assays, GFP localization, Co-immunoprecipitation, in vitro kinase inhibition assay\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro kinase assay with mutagenesis, Co-IP, and live-cell localization in a single study with multiple orthogonal methods\",\n      \"pmids\": [\"12651910\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Snk/PLK2 protein is targeted to dendrites of activated neurons following stimuli that produce synaptic plasticity (including LTP); a conserved C-terminal domain of Snk interacts specifically with CIB (Ca2+- and integrin-binding protein).\",\n      \"method\": \"Immunolocalization in neurons, yeast two-hybrid and binding assays for CIB interaction\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — direct localization experiment in neurons with functional context, interaction confirmed by binding assay, single lab\",\n      \"pmids\": [\"10523297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Plk2-deficient mouse embryonic fibroblasts grow more slowly and show delayed entry into S phase; Plk2-null embryos show retarded growth and decreased cell proliferation in the labyrinthine zone of the placenta, establishing a role for Plk2 in cell cycle progression.\",\n      \"method\": \"Gene-targeted knockout mice, BrdU incorporation, cell growth assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with defined cellular phenotype (delayed S-phase entry) confirmed in both primary cells and in vivo\",\n      \"pmids\": [\"12972611\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PLK2 directly phosphorylates alpha-synuclein at Ser-129 in vitro; PLK kinase inhibitors reduced pSer-129 alpha-synuclein in primary cortical cultures and mouse brain in vivo; specific shRNA knockdown or knockout of Plk2 reduced pSer-129 levels, establishing PLK2 as a principal kinase for this modification in the CNS.\",\n      \"method\": \"In vitro biochemical phosphorylation assay, pharmacological inhibition, shRNA knockdown, PLK2 knockout mice\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution of phosphorylation, confirmed by genetic KO and pharmacological inhibition across multiple systems\",\n      \"pmids\": [\"19004816\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PLK2 directly phosphorylates CPAP (centrosomal P4.1-associated protein, human SAS-4 homologue) at S589 and S595 in vitro and in vivo; this phosphorylation is critical for procentriole formation during the centrosome cycle; phospho-resistant CPAP mutant fails to form elongated centrioles.\",\n      \"method\": \"In vitro kinase assay, phospho-site mutagenesis, cell cycle stage-specific phosphorylation analysis, overexpression of phospho-resistant mutant\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with mutagenesis and functional validation (procentriole formation defect), single lab but multiple orthogonal methods\",\n      \"pmids\": [\"20531387\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The polo-box domain of PLK2 is required for its centrosomal localization; mutation of critical polo-box residues prevents centrosomal localization and impairs centriole duplication; PLK2 localizes exclusively to the mother centriole in early G1 then distributes to both centrioles at S phase onset; PLK2-mediated centriole duplication depends on PLK4 function.\",\n      \"method\": \"Polo-box mutagenesis, immunofluorescence localization, siRNA knockdown, spindle analysis\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization with functional consequence (centriole duplication), mutagenesis, single lab\",\n      \"pmids\": [\"19001868\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PLK2 directly interacts with NSF (N-ethylmaleimide-sensitive fusion protein) and disrupts the NSF-GluA2 interaction, promoting loss of surface GluA2 AMPAR subunit, greater association of GluA2 with PICK1 and GRIP1, and decreased synaptic AMPAR current; this effect requires PLK2-NSF engagement but not PLK2 kinase activity, and occurs through a motif in PLK2 independent of canonical polo-box sites.\",\n      \"method\": \"Co-immunoprecipitation, surface receptor assays, electrophysiology in rat hippocampal neurons, domain-mapping mutagenesis\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — reciprocal Co-IP, electrophysiology, and domain mutagenesis in a single study with multiple orthogonal methods\",\n      \"pmids\": [\"20802490\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Plk2 directs phosphorylation-dependent ubiquitin-proteasome degradation of RasGRF1 (Ras activator) and SPAR (Rap inhibitor), and phosphorylation-dependent stimulation of SynGAP (Ras inhibitor) and PDZGEF1 (Rap activator); collectively these actions suppress Ras and activate Rap signaling; perturbation of Plk2 prevents homeostatic shrinkage and loss of dendritic spines and impairs memory formation.\",\n      \"method\": \"Genetic epistasis, phosphorylation assays, ubiquitin-proteasome pathway assays, dendritic spine imaging, behavioral memory tasks\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple substrates identified and validated, genetic perturbation with defined cellular and behavioral phenotypes, replicated across Ras/Rap regulators\",\n      \"pmids\": [\"21382555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Plk2 directly phosphorylates Fbxw7 (human Cdc4/SCF ubiquitin ligase F-box protein) at serine 176; this phosphorylation destabilizes Fbxw7, leading to cyclin E accumulation and increased centriole duplication potential; the two proteins form a complex in vitro and in vivo.\",\n      \"method\": \"In vitro kinase assay, Co-immunoprecipitation, phospho-site mutagenesis, centriole counting assays\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with identified phosphosite, Co-IP in vitro and in vivo, functional centriole duplication assay, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"22399798\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PLK2 interacts with endogenous TSC1 protein; a C-terminal PLK2-GST fusion protein binds both TSC1 and TSC2; cells overexpressing PLK2 show decreased phosphorylation of p70S6K (downstream mTOR target) during hypoxia, indicating PLK2 modulates mTOR signaling via TSC1/2 interaction.\",\n      \"method\": \"Co-immunoprecipitation, GST pulldown, p70S6K phosphorylation assay, tumor xenografts\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — GST pulldown and Co-IP with functional mTOR readout, single lab\",\n      \"pmids\": [\"20054236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PLK2 binds to and phosphorylates mutant p53, potentiating its oncogenic transcriptional activity; phosphorylated mutant p53 binds more efficiently to p300; Plk2 gene is transcriptionally regulated by both wild-type and mutant p53, forming an autoregulatory feedback loop.\",\n      \"method\": \"Co-immunoprecipitation, kinase assay, transcriptional reporter assays, siRNA knockdown\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — Co-IP and kinase assay demonstrating direct interaction and phosphorylation, transcriptional assays, single lab\",\n      \"pmids\": [\"22134238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"PLK2 phosphorylates synGAP, shifting the ratio of synGAP GAP activity toward greater inactivation of HRas (65% increase) relative to Rap1 (16% increase); simultaneous phosphorylation by Plk2 and CDK5 at distinct sites produces additive increase in HRas GAP activity (~230%) and also increases GAP activity toward Rap2.\",\n      \"method\": \"In vitro kinase assay with recombinant synGAP, GTPase activity measurements, mass spectrometry identification of phosphosites\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution of kinase reaction with quantified substrate GAP activity, phosphosite identification by MS, single lab\",\n      \"pmids\": [\"30049443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PLK2 genetic knockout in mouse brain produces a gene-dosage-dependent reduction of endogenous Ser129-phosphorylated alpha-synuclein in all brain regions examined; pharmacological inhibition with pan-PLK inhibitor BI 2536 did not further reduce residual pSer-129 in PLK2 KO mice, indicating PLK2 is the primary but not sole kinase for this modification in vivo.\",\n      \"method\": \"PLK2 knockout mice, heterozygous mice, pharmacological inhibition with BI 2536, brain regional pSer-129 alpha-synuclein quantification\",\n      \"journal\": \"Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with dosage response, pharmacological epistasis, replicated across brain regions\",\n      \"pmids\": [\"24128992\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Alpha-synuclein is a substrate of yeast Cdc5 (PLK2 ortholog) and human PLK2; elevated levels of alpha-synuclein prevent Cdc5/Plk2 from maintaining normal GTP-bound Rho1 levels, disrupting MAPK stress signaling; the nine N-terminal amino acids of alpha-synuclein are essential for the interaction with polo-like kinases.\",\n      \"method\": \"Yeast genetics and biochemistry, GTP-Rho1 pull-down assay, N-terminal deletion mutagenesis of alpha-synuclein\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical interaction mapping with domain mutagenesis and GTPase assay, yeast and human cell experiments, single lab\",\n      \"pmids\": [\"22988096\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"PLK2 is superior to CK2 as a catalyst of alpha-synuclein Ser-129 phosphorylation; acidic residues at positions n-3 (Glu-126) and n+2 (Glu-131) flanking Ser-129 are critical determinants for phosphorylation by PLK2, as their replacement with alanine abrogates phosphorylation.\",\n      \"method\": \"In vitro kinase assay with full-length alpha-synuclein and substituted peptides, comparison with CK2\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase reconstitution with systematic peptide substitution mutagenesis defining substrate specificity determinants, single lab\",\n      \"pmids\": [\"22248692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PLK2 phosphorylates alpha-synuclein and promotes its selective degradation via macroautophagy; PLK2 and alpha-synuclein undergo co-degradation; the N-terminal region of alpha-synuclein is important for PLK2-mediated phosphorylation and physical interaction; PLK2 polyubiquitination is important for the PLK2-alpha-syn complex degradation by the macroautophagy machinery.\",\n      \"method\": \"Pharmacological and genetic inhibition of macroautophagy, domain mutagenesis, ubiquitination assays, Co-immunoprecipitation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — multiple complementary approaches (genetic/pharmacological autophagy inhibition, Co-IP, domain mapping), single lab\",\n      \"pmids\": [\"28154193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PLK2 directly phosphorylates TAp73 at Ser48 within the TA domain; phosphorylation is abolished by Ser48→Ala mutation; PLK2 physically binds TAp73; PLK2 inhibition combined with cisplatin leads to increased p21 and PUMA expression, cell cycle G1 arrest, increased apoptosis, and decreased invasion in TAp73-enriched osteosarcoma cells, effects absent in TAp73 knockdown cells.\",\n      \"method\": \"In vitro kinase assay, Co-immunoprecipitation, site-directed mutagenesis, siRNA knockdown, cell biology assays\",\n      \"journal\": \"Cancer medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — kinase assay with mutagenesis and functional validation, Co-IP, single lab\",\n      \"pmids\": [\"26625870\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PLK2 interacts with Chk2, Chk1, Ser317-phosphorylated Chk1, and p53 (by Co-immunoprecipitation); Plk2-deficient cells show higher H2AX Ser139 phosphorylation (indicating more DNA damage) and reduced Ser317-phosphorylated Chk1 under replication stress, indicating PLK2 contributes to S-phase checkpoint activation.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, phospho-specific western blotting, cell death assays with aphidicolin/etoposide\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — Co-IP demonstrating physical interactions, siRNA knockdown with checkpoint readout, single lab\",\n      \"pmids\": [\"17912033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SIRT1 deacetylates Plk2; acetylation of Plk2 protects it from ubiquitination, while SIRT1-mediated deacetylation promotes ubiquitin-dependent Plk2 degradation; AURKA phosphorylates SIRT1 and promotes the SIRT1-Plk2 interaction during mitosis; in early-mid G1 phosphorylated SIRT1 deacetylates and degrades Plk2, while in late G1 hypophosphorylated SIRT1 has reduced Plk2 affinity allowing Plk2 accumulation at centrosomes for centriole duplication.\",\n      \"method\": \"Co-immunoprecipitation, acetylation/ubiquitination assays, deacetylase assay, cell cycle synchronization, centrosome imaging\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal biochemical assays defining PTM writer/eraser/reader relationship and functional centrosome consequence, single lab\",\n      \"pmids\": [\"30517871\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PLK2 indirectly activates ROCK2 via phosphorylating nucleophosmin (NPM); PLK4 functions downstream of ROCK2 to drive centrosome amplification; epistasis rescue assay placed PLK2 upstream of ROCK2 upstream of PLK4 in a linear centrosome amplification pathway.\",\n      \"method\": \"Centrosome amplification rescue assay, siRNA knockdown epistasis, kinase activity assays\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with rescue assay placing PLK2 in linear pathway, single lab\",\n      \"pmids\": [\"25590559\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Plk2 regulates mitotic spindle orientation in mammary gland epithelium; loss of Plk2 leads to increased mammary epithelial cell proliferation, ductal hyperbranching, and loss of proper cell polarity, defining a role for Plk2 in spindle orientation and mammary gland development in vivo.\",\n      \"method\": \"Plk2 knockout mice, spindle orientation imaging, mammary gland morphology analysis, proliferation assays\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse with defined cellular phenotype (spindle misorientation, polarity loss), single lab\",\n      \"pmids\": [\"24598160\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"DYRK1A interacts with and phosphorylates PLK2 at Ser358; this phosphorylation increases PLK2 protein stability and markedly induces PLK2 kinase activity (evidenced by upregulation of alpha-synuclein S129 phosphorylation); DYRK1A-mediated PLK2 phosphorylation contributes to GBM cell proliferation, migration, and invasion.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, phospho-site mutagenesis, cell biology assays\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and kinase assay with mutagenesis and functional validation, single lab\",\n      \"pmids\": [\"37387444\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PLK2 phosphorylates SQSTM1/p62 at S349 following proteasome inhibition; this phosphorylation strengthens SQSTM1 binding to KEAP1, required for formation of large SQSTM1 aggregates/bodies; PLK2 is upregulated upon proteasome inhibition and associates with SQSTM1.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, phospho-site mutagenesis, aggregate formation assays, proteasome inhibition experiments\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro kinase assay with identified phosphosite, Co-IP, and functional aggregate formation assay with mutagenesis validation, single lab\",\n      \"pmids\": [\"39316746\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PLK2 phosphorylates DCTN1 (dynactin 1) at S1098, impairing autophagosome-lysosome fusion and blocking autophagic flux; PLK2 overexpression promotes SNCA/alpha-synuclein PFF-induced aggregation (including of phosphorylation-resistant SNCAS129A) and neurotoxicity independently of S129 phosphorylation; genetic or pharmacological PLK2 inhibition reduced SNCA deposition and motor dysfunction in vivo.\",\n      \"method\": \"In vitro kinase assay, phospho-site identification, autophagy flux assays (LC3, LAMP1), autophagosome-lysosome fusion imaging, in vivo mouse model with genetic PLK2 suppression\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro kinase assay with substrate identification, multiple autophagy assays, in vivo validation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"39773002\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Plk2 directly phosphorylates N-cadherin and promotes its proteolytic processing and degradation during neuronal hyperexcitation; Plk2 also disrupts N-cadherin complexes with APP; loss of N-cadherin adhesive function destabilizes excitatory synapses as part of homeostatic synaptic plasticity.\",\n      \"method\": \"In vitro kinase assay, Co-immunoprecipitation, proteolytic processing assays, synaptic imaging in neurons\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — direct kinase assay and Co-IP with functional synaptic readout, single lab\",\n      \"pmids\": [\"37654026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SKP1 directly interacts with PLK2 (by co-immunoprecipitation) and promotes PLK2 ubiquitination and protein degradation (by in vitro ubiquitination assay); reduced PLK2 due to SKP1-mediated degradation contributes to alpha-synuclein aggregation in neurons.\",\n      \"method\": \"Co-immunoprecipitation, in vitro ubiquitination assay, luciferase reporter for miRNA target validation\",\n      \"journal\": \"Journal of healthcare engineering\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Weak — Co-IP and in vitro ubiquitination assay from a single lab, modest methodological depth\",\n      \"pmids\": [\"34234930\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"FAM117B interacts with DYRK1A and acts as its upstream regulator; DYRK1A induces PLK2 phosphorylation in colorectal cancer cells, thereby upregulating PLK2 protein expression; the FAM117B/DYRK1A/PLK2 axis promotes CRC cell proliferation, migration, and invasion.\",\n      \"method\": \"Co-immunoprecipitation, immunoprecipitation-kinase assay, knockdown/overexpression rescue experiments, in vivo xenograft model\",\n      \"journal\": \"Cell biology international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — Co-IP and phosphorylation assay with functional epistasis rescue, single lab\",\n      \"pmids\": [\"41504297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PLK2 phosphorylates GSK3β, increasing its phosphorylation (inactivation); PLK2 overexpression reduces oxidative stress and apoptosis in cisplatin-treated renal cells and hepatic I/R models via increased GSK3β phosphorylation and downstream HO-1 antioxidant enzyme expression.\",\n      \"method\": \"PLK2 overexpression/siRNA knockdown, GSK3β phosphorylation western blotting, HO-1 expression assays, ROS measurement, in vivo AKI/I-R mouse models\",\n      \"journal\": \"Experimental cell research / Journal of gastroenterology and hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — gain/loss-of-function with kinase substrate (GSK3β) phosphorylation readout and functional consequence; replicated in two independent organ injury contexts\",\n      \"pmids\": [\"35523306\", \"39563073\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Structure-guided crystallography of PLK2-inhibitor complexes enabled design of brain-penetrant, isoform-selective PLK2 inhibitors; oral administration of lead compounds significantly decreased Ser129 alpha-synuclein phosphorylation in rat brain, pharmacologically validating PLK2 as the dominant kinase for this modification in vivo.\",\n      \"method\": \"Crystal structure of PLK2-inhibitor complex, kinome selectivity profiling, in vivo rat brain pharmacodynamics\",\n      \"journal\": \"ChemMedChem\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — first reported PLK2-inhibitor crystal structures used for structure-guided design, with in vivo pharmacodynamic validation\",\n      \"pmids\": [\"23794260\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"PLK2 phosphorylates HSP90, GRP-94, beta-tubulin, calumenin, and 14-3-3 epsilon in vitro; mass spectrometry identified the specific phosphosites generated by PLK2 on these substrates, revealing PLK2 substrate specificity determinants.\",\n      \"method\": \"Cell lysate kinase assay, 2D gel electrophoresis, mass spectrometry phosphosite identification\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro kinase assay with MS-based phosphosite identification on multiple substrates, single lab\",\n      \"pmids\": [\"22828320\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"KLF5 transcription factor directly binds to the PLK2 promoter (by ChIP-qPCR and dual-luciferase reporter assay) and transcriptionally activates PLK2 expression; elevated PLK2 inhibits chondrocyte autophagy and contributes to osteoarthritis progression.\",\n      \"method\": \"ChIP-qPCR, dual-luciferase reporter assay, PLK2 knockdown, autophagy markers (Beclin-1, LC3), OA mouse model\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding demonstrated by ChIP and luciferase with functional autophagy readout, single lab\",\n      \"pmids\": [\"41198759\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PLK2 (SNK) is a G1-phase serine/threonine polo-like kinase that is transcriptionally induced by p53 and neuronal activity; it phosphorylates a broad set of substrates including alpha-synuclein (Ser-129), CPAP/SAS-4 (centriole duplication), Fbxw7 (cyclin E stabilization), SQSTM1/p62 (aggrephagy), DCTN1 (autophagy flux), synGAP, RasGRF1, SPAR, N-cadherin, TAp73, mutant p53, NPM, and GSK3β; it is negatively regulated by CIB (Ca2+/integrin-binding protein) and SIRT1-mediated deacetylation/ubiquitination, and positively activated by DYRK1A-mediated phosphorylation at Ser358; through coordinated regulation of Ras and Rap GTPase regulators and AMPAR trafficking (via NSF disruption), PLK2 governs homeostatic synaptic plasticity, and through its centrosomal substrates it controls centriole duplication in a polo-box-dependent manner.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PLK2 (SNK) is a polo-like serine/threonine kinase that operates in two principal arenas: G1-phase control of the centrosome/cell cycle and activity-dependent homeostatic synaptic plasticity in neurons [#1, #2, #3]. Its kinase activity is detectable in G1, depends on the catalytic Lys-108 and the activation residue Thr-236, and is restrained by an autoinhibitory C-terminus and by the calcium/integrin-binding protein CIB [#1]. PLK2 is transcriptionally induced by p53, and its loss delays S-phase entry and slows proliferation in fibroblasts and embryos, linking it to a p53-dependent cell cycle/mitotic checkpoint program [#0, #3]. Through its polo-box domain PLK2 localizes to the mother centriole in early G1 and to both centrioles at S-phase onset, where it drives centriole duplication by phosphorylating CPAP/SAS-4 and destabilizing the SCF F-box protein Fbxw7 to permit cyclin E accumulation [#5, #6, #9]; its abundance at the centrosome is gated by SIRT1-mediated deacetylation and ubiquitin-dependent degradation [#19]. In neurons, PLK2 is targeted to dendrites following plasticity-inducing stimulation and enforces homeostatic synaptic downscaling by coordinately reprogramming Ras and Rap signaling — phosphorylation-dependent degradation of RasGRF1 and SPAR and activation of SynGAP and PDZGEF1 suppress Ras while activating Rap — and by a kinase-independent, NSF-binding mechanism that disrupts NSF-GluA2 to remove surface AMPARs [#7, #8, #12]. PLK2 is the principal kinase phosphorylating alpha-synuclein at Ser-129 in the CNS, recognizing acidic residues flanking the site and engaging the alpha-synuclein N-terminus, and it additionally controls alpha-synuclein handling through autophagy via substrates such as SQSTM1/p62 and DCTN1 [#4, #13, #15, #23, #24]. PLK2 activity is positively set by DYRK1A phosphorylation at Ser-358 and negatively set by CIB binding and SIRT1/SKP1-driven turnover [#19, #22, #26].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established that PLK2 is not a constitutive housekeeping kinase but a stimulus-targeted neuronal protein, showing it is delivered to dendrites of activated neurons during synaptic plasticity and binds CIB through a conserved C-terminal domain.\",\n      \"evidence\": \"Immunolocalization in stimulated neurons plus yeast two-hybrid/binding assays for CIB\",\n      \"pmids\": [\"10523297\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not define which substrates underlie the dendritic function\", \"Functional role of the CIB interaction not resolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined the biochemical activation logic of PLK2 and a first negative regulator, placing its activity in G1 and identifying CIB as an inhibitor.\",\n      \"evidence\": \"Site-directed mutagenesis (T236E, K108), in vitro kinase assays, GFP localization to the MTOC, and Co-IP with CIB\",\n      \"pmids\": [\"12651910\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological MTOC substrates not yet identified\", \"Mechanism of C-terminal autoinhibition relief in cells unresolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Connected PLK2 to the p53 network and to cell cycle progression, establishing it as a p53 transcriptional target with a mitotic-checkpoint and S-phase entry role.\",\n      \"evidence\": \"p53 target validation with siRNA knockdown plus paclitaxel/nocodazole death assays; gene-targeted KO mice with BrdU and growth assays\",\n      \"pmids\": [\"12897130\", \"12972611\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct cell-cycle substrates not identified in these studies\", \"Molecular basis of delayed S-phase entry unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified the centrosome localization determinant and the first centriole substrate, linking PLK2 polo-box function to procentriole formation.\",\n      \"evidence\": \"Polo-box mutagenesis and immunofluorescence (centriole localization, PLK4 dependence); in vitro kinase assay and phospho-resistant CPAP mutant\",\n      \"pmids\": [\"19001868\", \"20531387\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Hierarchy between PLK2 and PLK4 only partially mapped\", \"How CPAP phosphorylation drives elongation mechanistically unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Established PLK2 as the principal CNS kinase generating Ser-129 phosphorylated alpha-synuclein, the disease-associated modification.\",\n      \"evidence\": \"In vitro phosphorylation, pharmacological PLK inhibition, shRNA knockdown, and PLK2 KO mice measuring brain pSer-129\",\n      \"pmids\": [\"19004816\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Consequence of Ser-129 phosphorylation for synuclein aggregation not settled here\", \"Identity of residual non-PLK2 kinase activity unknown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Revealed a kinase-independent PLK2 function in synaptic plasticity, showing PLK2 binds NSF to disrupt NSF-GluA2 and remove surface AMPARs.\",\n      \"evidence\": \"Reciprocal Co-IP, surface receptor and electrophysiology assays in rat hippocampal neurons, domain-mapping mutagenesis\",\n      \"pmids\": [\"20802490\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the non-polo-box NSF-binding motif undefined\", \"How kinase-dependent and kinase-independent PLK2 activities are coordinated unresolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined the mechanism by which PLK2 enforces homeostatic synaptic downscaling through coordinated Ras-suppression and Rap-activation, and linked this to memory.\",\n      \"evidence\": \"Genetic epistasis, phosphorylation and ubiquitin-proteasome assays on RasGRF1, SPAR, SynGAP, PDZGEF1; spine imaging and behavioral memory tasks\",\n      \"pmids\": [\"21382555\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphosites on each GTPase regulator not all mapped here\", \"Whether all four substrates are phosphorylated in the same synapse unresolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Extended PLK2 into oncogenic p53 biology, showing it phosphorylates mutant p53 to potentiate its transcriptional activity in an autoregulatory loop.\",\n      \"evidence\": \"Co-IP, kinase assay, transcriptional reporter assays, siRNA knockdown\",\n      \"pmids\": [\"22134238\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Phosphosite on mutant p53 not defined\", \"In vivo relevance to tumor phenotypes untested here\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Expanded the centriole-duplication mechanism by showing PLK2 destabilizes Fbxw7 to drive cyclin E accumulation, and quantitatively defined PLK2 reshaping of SynGAP GTPase selectivity.\",\n      \"evidence\": \"In vitro kinase assays with phosphosite mapping (Fbxw7 S176; SynGAP by MS), Co-IP, GTPase activity measurements, centriole counting\",\n      \"pmids\": [\"22399798\", \"30049443\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Fbxw7 destabilization contributes to centriole amplification in vivo unresolved\", \"Integration of PLK2 and CDK5 SynGAP phosphorylation in intact synapses not tested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined the substrate-recognition determinants of PLK2 on alpha-synuclein and broadened its in vitro substrate repertoire.\",\n      \"evidence\": \"In vitro kinase assays with peptide substitution (Glu-126/Glu-131), comparison with CK2; cell-lysate kinase assay with MS phosphosite mapping (HSP90, GRP-94, beta-tubulin, calumenin, 14-3-3 epsilon); yeast Cdc5/Rho1 genetics\",\n      \"pmids\": [\"22248692\", \"22828320\", \"22988096\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In-cell relevance of the broad in vitro substrate set unverified\", \"Functional consequence of HSP90/tubulin/14-3-3 phosphorylation unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Pharmacologically and structurally validated PLK2 as the dominant in vivo Ser-129 alpha-synuclein kinase, enabling selective inhibitor development.\",\n      \"evidence\": \"PLK2-inhibitor crystal structures with kinome selectivity and in vivo rat brain pharmacodynamics; KO/heterozygote dosage study with BI 2536 epistasis\",\n      \"pmids\": [\"23794260\", \"24128992\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the residual non-PLK2 Ser-129 kinase unresolved\", \"Therapeutic consequence of reducing pSer-129 not established here\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrated an in vivo tissue-morphogenesis role, showing Plk2 controls mitotic spindle orientation and epithelial polarity in the mammary gland.\",\n      \"evidence\": \"Plk2 KO mice with spindle orientation imaging and mammary morphology/proliferation analysis\",\n      \"pmids\": [\"24598160\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Spindle-orientation substrate not identified\", \"Mechanistic link to centriole substrates unresolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Positioned PLK2 within centrosome-amplification and tumor-suppressor signaling pathways through NPM/ROCK2/PLK4 and TAp73 phosphorylation.\",\n      \"evidence\": \"Centrosome amplification epistasis/rescue assays; in vitro kinase assay and Co-IP for TAp73 S48 with cisplatin functional assays\",\n      \"pmids\": [\"25590559\", \"26625870\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct NPM phosphosite and ROCK2 activation mechanism partly unresolved\", \"TAp73 axis tested in limited cell contexts\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Linked PLK2 to alpha-synuclein clearance, showing PLK2 promotes macroautophagic co-degradation of phospho-synuclein and itself.\",\n      \"evidence\": \"Genetic/pharmacological autophagy inhibition, domain mapping, ubiquitination assays, Co-IP\",\n      \"pmids\": [\"28154193\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Autophagy receptor mediating PLK2/synuclein clearance not defined here\", \"Reconciliation with later flux-blocking role unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined the cell-cycle-timed PTM circuit controlling PLK2 abundance, with AURKA-phosphorylated SIRT1 deacetylating PLK2 to license its ubiquitin-dependent turnover and centrosomal accumulation.\",\n      \"evidence\": \"Co-IP, acetylation/ubiquitination/deacetylase assays, cell-cycle synchronization, centrosome imaging\",\n      \"pmids\": [\"30517871\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase acting on deacetylated PLK2 not identified\", \"Acetylated lysines on PLK2 not fully mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified SKP1-mediated ubiquitination as an additional route of PLK2 degradation relevant to alpha-synuclein aggregation.\",\n      \"evidence\": \"Co-IP, in vitro ubiquitination assay, miRNA target luciferase reporter\",\n      \"pmids\": [\"34234930\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab with modest methodological depth; not independently confirmed\", \"Relationship to SIRT1-dependent turnover pathway unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified DYRK1A as a positive upstream activator of PLK2 (Ser-358 phosphorylation increasing stability and activity) and added N-cadherin as a synaptic substrate, broadening upstream control and downstream effects.\",\n      \"evidence\": \"Co-IP and in vitro kinase assays with phosphosite mutagenesis; N-cadherin kinase/Co-IP and proteolytic processing assays with synaptic imaging\",\n      \"pmids\": [\"37387444\", \"37654026\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether DYRK1A control operates in neurons as well as cancer cells untested\", \"N-cadherin axis from a single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Expanded PLK2 into proteostasis and stress-protection roles via SQSTM1/p62 S349, GSK3beta inactivation, and KLF5-driven transcription, connecting PLK2 to aggrephagy, antioxidant signaling, and autophagy suppression.\",\n      \"evidence\": \"In vitro kinase assays with phosphosite mutagenesis, Co-IP, aggregate-formation assays; gain/loss-of-function with GSK3beta/HO-1/ROS readouts in two organ-injury models; ChIP-qPCR and luciferase for KLF5\",\n      \"pmids\": [\"39316746\", \"35523306\", \"39563073\", \"41198759\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"GSK3beta and KLF5 axes are largely single-context\", \"How aggrephagy-promoting and flux-blocking roles coexist unresolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Revealed a kinase-dependent but Ser-129-independent mechanism by which PLK2 drives synuclein pathology, phosphorylating DCTN1 (S1098) to block autophagosome-lysosome fusion and impair flux.\",\n      \"evidence\": \"In vitro kinase assay with phosphosite ID, autophagy flux/fusion imaging (LC3, LAMP1), in vivo mouse model with genetic PLK2 suppression\",\n      \"pmids\": [\"39773002\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How the same kinase both clears (macroautophagy) and blocks (flux) synuclein not reconciled\", \"Whether DCTN1 phosphorylation occurs in human disease tissue untested\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Placed PLK2 within a FAM117B/DYRK1A signaling axis promoting colorectal cancer phenotypes, extending the DYRK1A-PLK2 regulatory module to a new tumor context.\",\n      \"evidence\": \"Co-IP, IP-kinase assay, knockdown/overexpression rescue, in vivo xenograft\",\n      \"pmids\": [\"41504297\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct PLK2 substrates driving CRC phenotypes not identified\", \"Single-lab cancer-context finding\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How PLK2's distinct functional modes — kinase-dependent centriole/synaptic substrate phosphorylation, kinase-independent NSF disruption, and opposing pro- and anti-autophagic actions on alpha-synuclein — are selected within a single cell remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model integrating cell-cycle versus synaptic substrate selection\", \"No structural basis distinguishing polo-box-dependent versus NSF-binding modes\", \"Reconciliation of synuclein clearance versus flux-blocking roles missing\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [4, 5, 9, 12, 23, 24, 30]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [1, 4, 5, 9, 12]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [1]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [7, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005815\", \"supporting_discovery_ids\": [1, 6, 19]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [2]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [0, 3, 6, 9, 19]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [2, 7, 8, 25]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [16, 23, 24, 31]},\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [5, 6, 20]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [8, 10, 12, 28]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CIB1\", \"NSF\", \"Fbxw7\", \"SIRT1\", \"DYRK1A\", \"SKP1\", \"TSC1\", \"NPM1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}